Skip to main content
SpringerLink
Log in

Correcting anemia slows renal disease progression

  • Chapter
Renal Anemia

  • 110 Accesses

Abstract

Translating what is empirically established to a regimen designed to benefit an individual patient, in the absence of proof of efficacy, is the mainstay of medicine since its inception as a profession. Lacking evidence, but wanting to do good, is the rationale for “off label” extension of drugs as well as innovative though sometimes risky application of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albertazzi A, Di Liberato L, Daniele F, Battistel V, Colombi L. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Int J Artif Organs. 1998;21(1):12–8.

    PubMed  CAS  Google Scholar 

  2. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis. 2001;37(2):348–55.

    Article  PubMed  CAS  Google Scholar 

  3. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999;10(8):1793–800.

    PubMed  CAS  Google Scholar 

  4. Feinstein S, Becker-Cohen R, Algur N, Raveh D, Shalev H, Shvil Y, Frishberg Y. Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function. Am J Kidney Dis. 2001;37(4):736–42.

    Article  PubMed  CAS  Google Scholar 

  5. Ishimitsu T, Ono H, Sugiyama M, Asakawa H, Oka K, Numabe A, Abe M, Matsuoka H, Yagi S. Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Nephron. 1996;74(3):607–10.

    Article  PubMed  CAS  Google Scholar 

  6. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24(3):495–9.

    Article  PubMed  CAS  Google Scholar 

  7. Berman DH, Friedman EA. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina. 1994;14:1–5.

    PubMed  CAS  Google Scholar 

  8. Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis. 1995;26(1):202–8.

    Article  PubMed  CAS  Google Scholar 

  9. Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR, Hahn JS, Huh KB. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract. 1999;46(3):223–9.

    Article  PubMed  CAS  Google Scholar 

  10. Hadjadj S, Torremocha F, Fanelli A, Brizard A, Bauwens M, Marechaud R. Erythropoietin-dependent anaemia: a possible complication of diabetic neuropathy. Diabetes Metab. 2001;27(3):383–5.

    PubMed  CAS  Google Scholar 

  11. Ozaki H, Hayashi H, Oshima K. Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy. Ophthalmic Res. 1996;28:356–60.

    Article  PubMed  CAS  Google Scholar 

  12. Obrosova IG, Stevens MJ, Lang HJ. Diabetes-induced changes in retinal NAD-redox status pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology. 2001;62(3):172–80.

    Article  PubMed  CAS  Google Scholar 

  13. Kissun RD, Garner A. Vasoformative properties of normal and hypoxic retinal tissue. Br J Ophthalmol. 1977;61(6):394–8.

    Article  PubMed  CAS  Google Scholar 

  14. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13(1):37–50.

    Article  PubMed  CAS  Google Scholar 

  15. Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol. 1998;125:731–2.

    Google Scholar 

  16. Nissenson AR. Optimal hematocrit for hemodialysis. Curr Opin Nephrol Hypertens. 1997;6(6):524–7.

    Article  PubMed  CAS  Google Scholar 

  17. Basta E, Bakris GL.. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000;40:978–89.

    Article  PubMed  CAS  Google Scholar 

  18. Cinotti GA, Zucchelli PC. Collaborative Study Group. Effect of lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant. 2001;16(5):961–6.

    Article  PubMed  CAS  Google Scholar 

  19. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care. 2001;24(3):430–4.

    Article  PubMed  CAS  Google Scholar 

  20. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets for chronic renal failure in non diabetic adults (Cochrane Review). Cochrane Database Syst Rev. 2001;2:CD001892.

    Google Scholar 

  21. Schmitz PG. Progressive renal insufficiency. Office strategies to prevent or slow progression of kidney disease. Postgrad Med. 2000;108(1):145–8, 151–4.

    PubMed  CAS  Google Scholar 

  22. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35(4 supplement 1):S97–105.

    Article  PubMed  CAS  Google Scholar 

  23. Righetti M, Sessa A. Cigarette smoking and kidney involvement. J Nephrol. 2001;14(1):3–6.

    PubMed  CAS  Google Scholar 

  24. Murphy ST, Parfrey PS. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit. Curr Opin Nephrol Hypertens. 1999;8(5):573–8.

    Article  PubMed  CAS  Google Scholar 

  25. Macdougall IC. Quality of life and anemia: the nephrology experience. Semin Oncol. 1998;25(3 supplement 7):39–42.

    PubMed  CAS  Google Scholar 

  26. Johansen KL. Physical functioning and exercise capacity in patients on dialysis. Adv Ren Replace Ther. 1999;6(2):141–8.

    PubMed  CAS  Google Scholar 

  27. Brandberg Y. Quality of life in clinical trials: assessment and utility with special reference to rHuEPO. Med Oncol. 1998;15(supplement 1):S8–12.

    PubMed  Google Scholar 

  28. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant. 2000;15:1425–30.

    Article  PubMed  CAS  Google Scholar 

  29. Page DE, House A. Important cost differences of blood transfusions and erythropoietin between hemodialysis and peritoneal dialysis patients. Adv Perit Dial. 1998;14:87–9.

    PubMed  CAS  Google Scholar 

  30. Mocks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta — a retrospective study. Nephron. 2000;86(4):455–62.

    Article  PubMed  CAS  Google Scholar 

  31. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 2000;20(4):345–9.

    PubMed  CAS  Google Scholar 

  32. Macdougall IC. How to improve survival in pre-dialysis patients. Nephron 2000;85(supplement 1):15–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Eli A. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, New York, USA

    Onyekachi Ifudu (Associate Professor of Medicine, Director) (Associate Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Friedman, E.A. (2002). Correcting anemia slows renal disease progression. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9998-6_1

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6045-7

  • Online ISBN: 978-94-015-9998-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation